Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-17166864
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
JNJ-17166864 is a small molecule drug developed as an antagonist of the C-C chemokine receptor type 2 (CCR2). It was investigated primarily for immune and inflammatory conditions, including seasonal allergic rhinitis and inflammation. The compound acts by blocking CCR2, thereby inhibiting chemokine-mediated recruitment of inflammatory cells. The drug was originally developed by Johnson & Johnson Pharmaceutical Research & Development and Janssen Research & Development. Clinical development reached up to Phase 2 for seasonal allergic rhinitis (intranasal administration), but no recent reports indicate ongoing development or approval for any indication[2][4][7].
Beyond the preview
Go deeper on JNJ-17166864.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-17166864.